Xortx Therapeutics Inc (XRTX) Stock Price, Quote & News

Company Profile

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus;...

Industry: Biotechnology

Sector: Healthcare

Phone: 403-455-7727

Website: www.xortx.com

Address:

3710 - 33rd Street NW, Calgary, Canada

FreeBeerTomorrow Apr. 3 at 6:52 PM

$XRTX XORTX Therapeutics Inc. (XRTX) has a 1-for-5 reverse stock split scheduled to take effect this coming Monday, April 6, 2026. Recent market data shows the public float (the shares actually available for trading) was roughly 6.25 million shares. Post-split, this drops to approximately 1.25 million shares.

0 · Reply

TwongStocks Apr. 2 at 9:54 PM

A total of 11(!!!) NASDAQ reverse splits scheduled on Monday (markets are closed Friday). Expect trading to halt at 7:50pm ET tonight and resume at 9:00am ET Monday morning. I'll have to split this into 3 parts. Part 3 of 3 $LNKS 1 for 250. Will reduce outstanding Class A shares from approx 339.15m to approx 1.36m. $SKK 1 for 10. Will reduce outstanding shares from approx 24.38m to approx 2.44m. $WNW 1 for 100. Will reduce outstanding shares from approx 133.04m to approx 1.33m. $XRTX 1 for 5. Will reduce outstanding shares from approx 6.96m to approx 1.39m.

2 · Reply

TwongStocks Apr. 1 at 6:43 PM

$XRTX Equity Corporate Actions Alert #2026 - 214 Information Regarding the Reverse Stock Split and CUSIP Number Change for XORTX Therapeutics Inc. (XRTX) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-214 XORTX Therapeutics Inc. (XRTX) will effect a one-for-five (1-5) reverse split of its common shares. The reverse stock split and change in CUSIP number will become effective on Monday, April 6, 2026. In conjunction with the reverse split, the CUSIP number will change to 98420Q405.

0 · Reply

DARKP00L Mar. 27 at 12:32 PM

$XRTX 08:32 on Mar. 27 2026 XORTX Therapeutics shares are trading lower after the company announced the delay of its 1-for-5 reverse stock split to April 6, 2026. #tradeideas

0 · Reply

topstockalerts Mar. 27 at 11:07 AM

Pre Market Top Gainers PT2 $GMEX $XRTX $SGML $HSCS $MNTK

0 · Reply

topstockalerts Mar. 26 at 10:14 PM

After Hours Top Gainers PT2 $NSYS $MKDW $HIND $SIGA $XRTX

2 · Reply

warm_it_up Mar. 26 at 3:51 PM

$XRTX this thing will have a micro float. Hopefully, they follow with good news. Just beware of offering if so!

0 · Reply

LookaLike Mar. 25 at 11:52 AM

$XRTX shareholders approved a 5 to 1 share consolidation

0 · Reply

LookaLike Mar. 23 at 5:02 PM

$XRTX buy now or after the Reverse split in April?

0 · Reply

BigTimePennyStocks Mar. 22 at 5:33 PM

Small-Caps with Catalysts this week: 👇👇 ( $SCNI, $XRTX, $RCKT, $BRTX, $BEAT, etc...) #NASDAQ #NYSE

1 · Reply

XORTX Confirms Effective Date of Share Consolidation

Thu, 26 Mar 2026 18:00:00 -0400 - 9 days ago

XORTX Announces Results of Annual and Special Meeting of Shareholders

Thu, 26 Mar 2026 16:32:00 -0400 - 9 days ago

XORTX Announces Change of Effective Date of Share Consolidation

Wed, 25 Mar 2026 18:15:00 -0400 - 10 days ago

XORTX Announces Share Consolidation

Fri, 13 Mar 2026 07:00:00 -0400 - 23 days ago

XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation

2026-03-05T12:33:09.000Z - 4 weeks ago

XORTX Therapeutics (XRTX) Announces Key Shareholder Meeting Agenda

2026-02-05T09:34:03.000Z - 2 months ago

Why Align Technology Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

2026-02-05T07:10:06.000Z - 2 months ago

XORTX Extends Closing Of Renal Anti-Fibrotic Therapeutic Program Acquisition; Stock Soars

Tue, 21 Oct 2025 08:00:00 -0400 - 5 months ago

XORTX Announces Pricing of US$1.1 Million Registered Direct Offering

2025-10-21T06:55:29.000Z - 5 months ago

XORTX Therapeutics (XRTX) Secures Nasdaq Extension to Meet Bid Price Rule

Mon, 20 Oct 2025 20:34:00 -0400 - 5 months ago

XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

Mon, 20 Oct 2025 18:45:00 -0400 - 5 months ago

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

2025-10-17T12:35:39.000Z - 6 months ago

XORTX (XRTX) Acquires Renal Therapeutic Program from Vectus

Fri, 17 Oct 2025 07:00:00 -0400 - 6 months ago

XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

2025-09-09T13:01:00.000Z - 7 months ago

XORTX Therapeutics goes ‘toe to toe’ with gout by accelerating its lead drug program targeting this complex disease

Wed, 03 Sep 2025 07:00:00 -0400 - 7 months ago

XORTX Initiates IND Preparation for XORLO™ in Gout Program

Fri, 08 Aug 2025 19:54:00 -0400 - 8 months ago

XORTX Completes USD $114,500 Private Placement

Tue, 22 Jul 2025 19:59:00 -0400 - 9 months ago

XORTX Completes Non-Brokered Private Placement of Units

Thu, 26 Jun 2025 07:00:00 -0400 - 10 months ago

XORTX Announces USD $925,000 Private Placement

Mon, 19 May 2025 07:00:00 -0400 - 11 months ago

XORTX Announces USD $3 Million Offering

2025-04-18T07:55:25.000Z - 1 year ago

XORTX Therapeutics (XRTX) Faces Nasdaq Compliance Challenge

Thu, 17 Apr 2025 19:45:00 -0400 - 1 year ago

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

2025-02-15T11:02:46.000Z - 1 year ago

ARMISTICE CAPITAL, LLC Acquires Shares in XORTX Therapeutics Inc

Fri, 17 Jan 2025 17:00:00 -0500 - 1 year ago

XORTX Announces Change of Auditor

2024-12-13T07:01:58.000Z - 1 year ago

IRW-News: XORTX Therapeutics Inc.: XORTX kündigt Präsentation auf dem Rare and Genetic Disease Summit an

Thu, 12 Dec 2024 09:17:00 -0500 - 1 year ago

XORTX Announces Presentation at the Rare and Genetic Disease Summit

Fri, 18 Oct 2024 16:00:00 -0400 - 1 year ago

XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement

Wed, 09 Oct 2024 05:00:00 -0400 - 1 year ago

XORTX Initiates Precision Medicine Program

Fri, 13 Sep 2024 07:00:00 -0400 - 1 year ago

XORTX Announces Results of Annual and Special Meeting of Shareholders

Thu, 12 Sep 2024 17:30:00 -0400 - 1 year ago

XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A

Fri, 06 Sep 2024 17:30:00 -0400 - 1 year ago

XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders

Tue, 03 Sep 2024 12:30:00 -0400 - 1 year ago

Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders

Fri, 23 Aug 2024 07:00:00 -0400 - 1 year ago

XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders

Tue, 20 Aug 2024 07:00:00 -0400 - 1 year ago

XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024

Fri, 17 May 2024 07:00:00 -0400 - 2 years ago

XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO

Tue, 30 Apr 2024 13:54:00 -0400 - 2 years ago

XORTX Reprices Warrants Issued in Connection with Previous Private Placements

Mon, 22 Apr 2024 07:00:00 -0400 - 2 years ago

XORTX Announces Publication of Key Research in ADPKD

Mon, 08 Apr 2024 07:30:00 -0400 - 2 years ago

XORTX Welcomes New Member to the Board of Directors

Wed, 27 Mar 2024 05:00:00 -0400 - 2 years ago

XORTX Announces New Clinical Advisory Board Member

Tue, 19 Mar 2024 05:00:00 -0400 - 2 years ago

XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial

Mon, 04 Mar 2024 07:00:00 -0500 - 2 years ago

XORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of Units

Thu, 01 Feb 2024 20:46:00 -0500 - 2 years ago

XORTX Files an Amended and Restated Prospectus Supplement for the Offering of Units

Mon, 15 Jan 2024 07:00:00 -0500 - 2 years ago

XORTX Announces $2 Million Public Offering

Wed, 03 Jan 2024 07:00:00 -0500 - 2 years ago

XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease

Thu, 30 Nov 2023 07:30:00 -0500 - 2 years ago

XORTX Announces US ATM Offering

Wed, 29 Nov 2023 07:00:00 -0500 - 2 years ago

XORTX Meets Nasdaq Continued Listing Requirements

Fri, 10 Nov 2023 07:00:00 -0500 - 2 years ago

XORTX Clarifies Timing for Share Consolidation

Wed, 08 Nov 2023 17:00:00 -0500 - 2 years ago

XORTX Announces Share Consolidation

Fri, 27 Oct 2023 17:30:00 -0400 - 2 years ago

XORTX Announces Results of Special Meeting of Shareholders

Oct 25, 2023, 5:00 PM EDT - 2 years ago

XORTX Announces Date for Rescheduled Special Meeting of Shareholders

Oct 25, 2023, 7:00 AM EDT - 2 years ago

XORTX Announces Rescheduling of Special Meeting of Shareholders

Oct 12, 2023, 7:00 AM EDT - 2 years ago

XORTX Reports that Independent Proxy Firm, ISS, Recommends Shareholders Vote for the Share Consolidation Resolution

Oct 4, 2023, 7:00 AM EDT - 2 years ago

XORTX Calls Special Meeting of Shareholders

Aug 29, 2023, 7:00 AM EDT - 2 years ago

XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease

Aug 4, 2023, 5:00 PM EDT - 2 years ago

XORTX Appoints Chief Financial Officer

Jun 23, 2023, 8:51 PM EDT - 3 years ago

XORTX Reminds Shareholders to Vote ahead of the Proxy Voting Deadline for the Company's Upcoming Annual and Special Meeting of Shareholders

May 24, 2023, 7:00 AM EDT - 3 years ago

XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

Apr 21, 2023, 7:00 AM EDT - 3 years ago

XORTX Announces Receipt of FDA Orphan Drug Designation to Treat Autosomal Dominant Kidney Disease

Feb 1, 2023, 7:00 AM EST - 3 years ago

XORTX Announces Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Disease

Jan 19, 2023, 7:00 AM EST - 3 years ago

XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial

FreeBeerTomorrow Apr. 3 at 6:52 PM

0 · Reply

TwongStocks Apr. 2 at 9:54 PM

2 · Reply

TwongStocks Apr. 1 at 6:43 PM

0 · Reply

DARKP00L Mar. 27 at 12:32 PM

$XRTX 08:32 on Mar. 27 2026 XORTX Therapeutics shares are trading lower after the company announced the delay of its 1-for-5 reverse stock split to April 6, 2026. #tradeideas

0 · Reply

topstockalerts Mar. 27 at 11:07 AM

Pre Market Top Gainers PT2 $GMEX $XRTX $SGML $HSCS $MNTK

0 · Reply

topstockalerts Mar. 26 at 10:14 PM

After Hours Top Gainers PT2 $NSYS $MKDW $HIND $SIGA $XRTX

2 · Reply

warm_it_up Mar. 26 at 3:51 PM

$XRTX this thing will have a micro float. Hopefully, they follow with good news. Just beware of offering if so!

0 · Reply

LookaLike Mar. 25 at 11:52 AM

$XRTX shareholders approved a 5 to 1 share consolidation

0 · Reply

LookaLike Mar. 23 at 5:02 PM

$XRTX buy now or after the Reverse split in April?

0 · Reply

BigTimePennyStocks Mar. 22 at 5:33 PM

Small-Caps with Catalysts this week: 👇👇 ( $SCNI, $XRTX, $RCKT, $BRTX, $BEAT, etc...) #NASDAQ #NYSE

1 · Reply

honestrick Mar. 11 at 8:27 PM

$SXTP Will $XRTX be next ? GLTA .

0 · Reply

honestrick Mar. 9 at 4:00 PM

$XRTX Did anyone get the package and vote yet on the annual meeting proposals yet ?

0 · Reply

VintageVibes Mar. 9 at 5:34 AM

$XRTX Looks like a good buy zone?

1 · Reply

A_I_Bot Mar. 5 at 7:13 PM

$XRTX "Compliance Requirement: To regain compliance, the company's common stock must close at or above $1.00 for a minimum of 10 consecutive business days before the April 13, 2026 deadline"

0 · Reply

warm_it_up Mar. 4 at 12:48 PM

$XRTX you know why I like this ticker? You never have to worry about it. It's perpetually red, so there's never a need to check it!

0 · Reply

OfficialStocktwitsUser Mar. 4 at 2:11 AM

$XRTX RSI: 42.44, MACD: -0.0311 Vol: 0.03, MA20: 0.42, MA50: 0.51 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

honestrick Feb. 27 at 3:54 PM

$DRUG $NVDA Just sell 50 shares and buy $XRTX .Help a guy out ,You never know what they will announce at there webcast in March .

1 · Reply

honestrick Feb. 27 at 3:14 PM

$NVDA $XRTX markets red to green ? GLTA

0 · Reply

aafetygod Feb. 27 at 2:27 PM

$XRTX Even if it shoots up right now, it probably won't go higher than 0.5... Personally, I hope this stock drops to the 0.15-0.2 range.

0 · Reply

BillionerOfKing Feb. 23 at 3:52 PM

$XRTX Current Stock Price: $0.40

0 · Reply

aafetygod Feb. 21 at 4:13 AM

$XRTX 0.1-0.2? 0.1, 0.2->0.5?

0 · Reply

honestrick Feb. 10 at 7:49 PM

$XRTX Volume coming in heavy for this stock ,any suggestions? $NVDA $DRUG $AAPL

0 · Reply

Market Cap	2.99M
Revenue (ttm)	0.00
Net Income (ttm)	-2.66M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	92,500
Avg Vol	170,218
Day's Range	N/A - N/A
Shares Out	6.96M
Stochastic %K	71%
Beta	0.46
Analysts	Strong Buy
Price Target	$14.00